| 11. |
|
|
| 12. |
- Janulaityte-Gunther, D, et al.
(författare)
-
Helicobacter pylori antibodies and gastric cancer: a gender-related difference
- 2005
-
Ingår i: Pathogens and Disease. - : Oxford University Press (OUP). - 2049-632X. ; 44:2, s. 191-195
-
Tidskriftsartikel (refereegranskat)abstract
- Helicobacter pylori has been proposed as a causative agent of gastric cancer. The aim of this study was to define serum antibodies response against different H. pylori antigens in patients with gastric cancer. Serum samples were collected from 115 Lithuanian patients with non-cardia gastric cancer and 110 age- and sex-matched controls without cancer. Heat-stable, low-molecular-mass, and outer membrane proteins were used as antigens to analyze serum IgG antibody response against H. pylori by enzyme-linked immunosorbent assay. Seroprevalence of H. pylori using low-molecular-mass antigen was significantly higher in gastric cancer patients, compared to controls (77% versus 57%, p < 0.05). Significant differences in the prevalence of H. pylori infection between gastric cancer patients and controls were found in females using all three studied antigens: heat-stable (98% versus 84%, p < 0.05), low-molecular-mass (88% versus 48%, p < 0.05) and outer membrane proteins (78% versus 57%, p < 0.05). In males, no significant differences were revealed between gastric cancer patients and controls. There may be other cofactors in addition to H. pylori that are important for the development of gastric cancer. H. pylori seems, however, to be a more important for development of gastric cancer in females than in males or males may have more confounding risk factors for gastric cancer than females.
|
|
| 13. |
- Londo, Marc, et al.
(författare)
-
Eyes on the track, mind on the horizon: The REFUEL EU Road Map for biofuels
- 2008
-
Ingår i: Proceedings of the 16th European Biomass Conference & Exhibition - From research to industry and markets, Feria Valencia, Spain, 2-6 June 2008.
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- The current hot debate on biofuels calls for a balanced and realistic long-term strategy for biofuels. The REFUEL project provides several ingredients for such a strategy. Analyses in this project indicate that domestically produced biofuels can cover a significant share of EU fuel demand in the coming decades, with the EU-12 new member states and Ukraine as most promising regions. This potential can be realised with residual streams and on existing agricultural land, without conversion of e.g. nature reserves. Second-generation biofuels are essential for the long-term success of biofuels due to their superior performance in many ways. But generally, the key challenge for the near future would be how to enhance the development of biofuels in a responsible way, i.e. stimulating the production chains with the best performance, and preventing negative impacts e.g., by paying careful attention to possible system impacts of biofuel production such as indirect land use changes and rising food prices. Finally, 2nd generation biofuels require specific policy: the precursor role of 1st generation is overrated, both in technical terms as well as in their role as market precursors. When it comes to synergies, 2nd generation biofuels might benefit more from other developments in the energy sector, such as initiatives in co-firing of biomass for (heat and) power, than from 1st generation biofuels, also because of the public resistance that the latter induce.
|
|
| 14. |
- Londo, Marc, et al.
(författare)
-
REFUEL: an EU road map for biofuels
- 2007
-
Ingår i: Proceedings of the Risø International Energy Conference 2007, 22-24 May.
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- A successful mid-term development of biofuels calls for a robust road map. REFUEL assesses inter alia least-cost biofuel chain options, their benefits, outlines the technological, legislative and other developments that should take place, and evaluate different policy strategies for realisation. Some preliminary conclusions of the project are discussed here. There is a significant domestic land potential for energy crops in the EU, which could supply between one quarter and one third of gasoline and diesel demand by 2030 if converted into advanced biofuels. A biomass supply of 8 to 10 EJ of primary energy could be available at costs around or below 3 €/GJ. However, the introduction of advanced biofuel options may meet a considerable introductory cost barrier, which will not be overcome when EU policy is oriented to the introduction of biofuels at least cost. Therefore, conventional biodiesel en ethanol may dominate the market for decades to come, unless biofuels incentives are differentiated, e.g. on the basis of the differences in greenhouse gas performance among biofuels.The introduction of advanced biofuels may also be enhanced by creating stepping stones or searching introduction synergies. A stepping stone can be the short-term development of lignocellulosic biomass supply chains for power generation by co-firing; synergies can be found between advanced FT-diesel production and hydrogen production for the fuel cell.
|
|
| 15. |
|
|
| 16. |
- Zhang, W, et al.
(författare)
-
EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
- 2005
-
Ingår i: Annals of the Rheumatic Diseases. - : BMJ. - 1468-2060 .- 0003-4967. ; 64:5, s. 669-681
-
Forskningsöversikt (refereegranskat)abstract
- Objective: To develop evidence based recommendations for the management of hip osteoarthritis (OA). Methods: The multidisciplinary guideline development group comprised 18 rheumatologists, 4 orthopaedic surgeons, and 1 epidemiologist, representing 14 European countries. Each participant contributed up to 10 propositions describing key clinical aspects of hip OA management. Ten final recommendations were agreed using a Delphi consensus approach. Medline, Embase, CINAHL, Cochrane Library, and HTA reports were searched systematically to obtain research evidence for each proposition. Where possible, outcome data for efficacy, adverse effects, and cost effectiveness were abstracted. Effect size, rate ratio, number needed to treat, and incremental cost effectiveness ratio were calculated. The quality of evidence was categorised according to the evidence hierarchy. The strength of recommendation was assessed using the traditional A - D grading scale and a visual analogue scale. Results: Ten key treatment propositions were generated through three Delphi rounds. They included 21 interventions, such as paracetamol, NSAIDs, symptomatic slow acting disease modifying drugs, opioids, intra-articular steroids, non-pharmacological treatment, total hip replacement, osteotomy, and two general propositions. 461 studies were identified from the literature search for the proposed interventions of efficacy, side effects, and cost effectiveness. Research evidence supported 15 interventions in the treatment of hip OA. Evidence specific for the hip was strikingly lacking. Strength of recommendation varied according to category of research evidence and expert opinion. Conclusion: Ten key recommendations for the treatment of hip OA were developed based on research evidence and expert consensus. The effectiveness and cost effectiveness of these recommendations were evaluated and the strength of recommendation was scored.
|
|
